Regulation of Schwann cell proliferation and migration by neurotrophic factor after peripheral
R
A
P
ShengYi*, YingYuan*, Qianqian Chen, XinghuiWang, Leilei Gong, Jie Liu, Xiaosong Gu & Shiying Li
Peripheral nerve injury aects up to 2.8% of trauma patients and leads to high rates of morbidity and healthcare expenditure1,2. Although adult mammalian peripheral nervous system has a certain degree of capacity for axonal regrowth and nerve regeneration, the regeneration rate of injured peripheral nerves is slow and the functional recovery from spontaneous peripheral nerve repair is generally far from satisfactory35. Therefore, the development of medical therapies to improve peripheral nerve regeneration has attracted much attention, while molecular cues, especially growth factors, are oen used to enhance the efficacy of some medical therapies.
Neurotrophic factors are a family of growth factors that support and inuence the growth and regenerative capacity of neurons6. As a member of neurotrophic factors, brain-derived neurotrophic factor (BDNF) can be produced and secreted by Schwann cells (SCs) following peripheral nerve injury. An elevated level of BDNF prevents neuronal death, enhances neuronal activity, and promotes axon growth79. Inversely, a reduced level of BDNF retards neurite elongation and inhibits axon regrowth and remyelination1012. Obviously, BDNF plays important roles in peripheral nerve development and regeneration. Clinical use of exogenous BDNF, however, is limited by its short half-life, potential side eects, and delivery problems13,14. Therefore, searching for an eective strategy for clinical application of BDNF in peripheral nerve repair has become an interesting topic in recent years.
MicroRNAs (miRNAs, miRs) are endogenous small single-strand non-coding RNA molecules of ~22 nucleotides in length. They regulate the expressions of their complementary mRNAs at the post-transcriptional level, and thereby aect a wide variety of physiological and pathological processes, which include neurogenesis, neuronal maturation, and the development and regeneration of the nervous system among others15,16. Following
Jiangsu Key Laboratory of Neuroregeneration, Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China. *These authors contributed equally to this work. Correspondence and requests for
SCIENTIFIC REPORTS
1
www.nature.com/scientificreports/
peripheral nerve injury, the expressions of various miRNAs are altered in a time-dependent manner, and these dierentially expressed miRNAs regulate biological behaviors of neural cells (neurons and SCs), such as neuronal survival, neurite outgrowth, SC proliferation, SC migration, and axon remyelination by SCs17.
We have previously identied that a number of miRNAs and mRNAs are dierentially expressed aer sciatic nerve injury18,19. These data from microarray analysis suggested that the expression of BDNF was up-regulated following sciatic nerve injury and the expression prole of BDNF was opposite to that of miR-1. It is easily assumed that miR-1 may negatively regulate the BDNF expression and further mediate peripheral nerve regeneration. In the current study, therefore, we aimed to identify whether BDNF was a direct target of miR-1 and to determine how miR-1 together with BDNF aected peripheral nerve regeneration. We found that there existed 3 binding sites of miR-1 at the 3-UTR of BDNF. Target site 3, by mediating the mRNA degradation of BDNF, played the most signicant role among these 3 target sites. Through direct binding, miR-1 reduced the mRNA expression, the protein expression, and the secretion of BDNF, and meanwhile inhibited SC proliferation and migration. These ndings will contribute to understanding the molecular mechanisms regulating peripheral nerve regeneration, and will lead to a new strategy for applying BDNF in peripheral nerve repair.
Adult, male Sprague-Dawley (SD) rats were obtained from the Animal Experiment Center of Nantong University in China. The animals underwent sciatic nerve crush as described previously20. Briey, aer anaesthetization, the sciatic nerve at 10mm above the bifurcation into the tibial and common bular nerves was crushed twice. The injured nerve segments of 0.3cm in length, together with both nerve ends of 0.1cm in length, were harvested at 0, 1, 4, 7, and 14 days post nerve injury (PNI), respectively.
All animal procedures were performed in accordance with Institutional Animal Care guideline of Nantong University and were ethically approved by the Administration Committee of Experimental Animals in Jiangsu Province, China.
Primary SCs were isolated from the sciatic nerve of 1-day-old SD rats and further treated with anti-Thy1.1 antibody (Sigma, St Louis, MO) and rabbit complement (Invitrogen, Carlsbad, CA) to remove the broblasts as described previously21. The nal cell preparation consisted of 98% SCs, as determined by immunocytochemistry with SC marker anti-S100 (DAKO, Carpinteria, CA). A rat SC line (RSC96) was purchased from the American Type Culture Collection.
Primary SCs and RSC96 SCs were cultured in Dulbeccos modied eagle medium (DMEM) containing 10% fetal bovine serum (FBS) in a humidied 5% CO2 incubator at 37 C. Primary SCs were passaged for no more than 3 times prior to use.
SC cultures were transfected with miR-1 mimic, miR-1 inhibitor, or BDNF siRNA (Ribobio, Guangzhou, China), respectively, using Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the manufacturers instructions.
miRNA target prediction programs (TargetScan and MiRanda) were used to predict the binding sites of miR-1 on BDNF. The 3 untranslated region (3-UTR) of BDNF was amplified by PCR using rat genomic DNA as a template. The PCR products were subcloned into the region directly downstream of the stop codon in the luciferase gene in the luciferase reporter vector to generate p-Luc-UTR reporter plasmid. Overlap PCR was used to construct 3-UTR mutant reporter plasmid. Primers used to generate wild type and mutant BDNF 3-UTR were as follows: BDNF 3-UTR: CCGGAATTCGGACATATCCATGACCAGA, CCGCTCGAGGGATGGAGGCCATAAATGGA; BDNF 3-UTR mutant 1: CTGCATTACATAGGTCGATAATGTTGTGGTTTG, CAACATTATCGACCTATGT AATGCAGACTTTTA; BDNF 3-UTR mutant 2: GAACCAAAACATAGGGTTTACATTTTAGACACTA, TAAA ATGTAAACCCTATGTTTTGGTTCAAATTT; BDNF 3-UTR mutant 3: TACTTGAGACATAGGTAAAGG AAGGCTCGGAAG, GCCTTCCTTTACCTATGTCTCAAGTACCATTC. The sequences of wild-type and mutant 3-UTR were conrmed by sequencing.
For luciferase assay, HEK 293T cells were seeded in 24-well plates and co-transfected with a mixture of 120ng p-Luc-UTR, 20 pmol miRNA mimics, and 20 ng Renilla luciferase vector pRL-CMV (Promega, Madison, WI) using the Lipofectamine 2000 transfection system (Invitrogen). At 36h aer transfection, the rey and Renilla luciferase activities were measured using the dual-luciferase reporter assay system (Promega) from the cell lysates.
Total RNA was extracted using Trizol (Life technologies, Carlsbed, CA) according to manufacturers instructions. Contaminating DNA was removed using RNeasy spin columns (Qiagen, Valencia, CA). The quality of isolated RNA samples was evaluated using Agilent Bioanalyzer 2100 (Agilent technologies, Santa Clara, CA) and the quantity of RNA samples was determined using NanoDrop ND-1000 spectrophotometer (Innigen Biotechnology Inc., City of Industry, CA). A total amount of 20 ng RNA samples was reversely transcribed using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and stem-loop RT primers (Ribobio) according to manufacturers instructions to determine miR-1 expression. RNA samples were reversely transcribed to cDNA using a Prime-Script reagent Kit (TaKaRa, Dalian, China) according to manufacturers instructions to determine BDNF expression. Quantitative real-time RTPCR was performed using SYBR Green Premix Ex Taq (TaKaRa) with BDNF primer on an Applied Biosystems Stepone real-time PCR System. The sequences of BDNF primer were as follows: CAGGGGCATAGACAAAAG, CTTCCCCTTTTAATGGTC. The thermocycler program was as follows: 5 min at 94 C; 30 cycles of 30sec at 94 C, 45sec at 58 C, 30sec at 72 C; and 5 min at 72C. All reactions were run in
SCIENTIFIC REPORTS
2
www.nature.com/scientificreports/
triplicate. Relative expressions of miR-1 and BDNF were conducted using the comparative 2Ct method with U6 and GAPDH as the reference gene, respectively.
Protein lysates were extracted from lesioned sciatic nerve tissues or cell cultures through direct homogenization, and lysis in a Laemmli sample buer (2% SDS, 52.5mM Tris-HCl, and protein inhibitors). The protein concentration was determined by the Micro BCA Protein Assay Kit (Pierce, Rockford, IL). Protein lysates were mixed with -mercaptoethanol, glycerin, and bromophenol-blue, and allowed to incubate at 95 C for 5 min. Equal amounts of protein were separated on 12% SDS-polyacrylamide gels. Following electrophoresis, proteins were transferred onto polyvinylidene uoride (PVDF) membranes (Bio-Red, Hercules, CA). Membranes were blocked with 5% non-fat dry milk in PBS with 0.1% Tween-20 for 2h, probed with primary BDNF antibody (Abcam, Cambridge, MA) overnight at 4C, incubated in horseradish peroxidase (HRP)-conjugated secondary antibody (Pierce), developed with enhanced chemiluminescence rea-gent (Cell Signaling, Beverly, MA), and exposed to Kodak X-Omat Blue Film (NEN life science, Boston, MA). Quantication of band signal intensity was conducted with Grab-it 2.5 and Gelwork soware.
Primary SCs or RSC96 SCs were transfected with miR-1 mimic and control, miR-1 inhibitor and control, BDNF siRNA and control, respectively, using Lipofectamine RNAiMAX transfection reagent (Invitrogen). Aer incubation for 24 h, the medium of transfected SCs was replaced with FBS-free medium for addition 48h incubation. The medium was then taken out and ltered through a 0.22m lter (Millipore, Bedford, MA) to furnish the supernatant. The protein levels of BDNF in the medium were measured using a ChemiKine BDNF ELISA Kit (Millipore) according to the manufacturers instructions. Data were measured and summarized from 3 independent experiments, each comprising triplicate wells.
Primary SCs were resuspended in fresh pre-warmed (37 C) complete medium, counted, and then plated on poly-L-lysine-coated 96-well plates at a density of 3 105 cells/ml. At 36 h aer transfection, 100M 5-ethynyl-20-deoxyuridine (EdU) was applied to cell culture. Aer additional incubation for 24h, cells were xed with 4% paraformaldehyde in phosphate buered saline (PBS) for 30min. The proliferation rate of SCs was determined using Cell-Light EdU DNA Cell Proliferation Kit (Ribobio) according to the manufacturers protocol. The ratio of EdU-positive cells to total cells was calculated using images of randomly selected elds obtained under a DMR uorescence microscope (Leica Microsystems, Bensheim, Germany). Assays were performed 3 times using triplicate wells.
The migration ability of SCs was examined using 6.5mm Transwell chambers with 8m pores (Costar, Cambridge, MA). The bottom surface of each membrane was coated with 10g/ml bronectin. 100 l Primary SCs (3 105 cells/ml) were resuspended in DMEM and transferred to the top chambers of each transwell to allow their migration in a humidied 5% CO2 incubator at 37C with 500l complete medium being pipetted into the lower chambers. The upper surface of each membrane was cleaned with a cotton swab at the indicated time point. Cells adhering to the bottom surface of each membrane were stained with 0.1% crystal violet and then counted under a DMR inverted microscope (Leica Microsystems). Assays were performed 3 times using triplicate wells.
All numerical results were reported as means SEM. The students t-test was used for statistical analyses by the aid of SPSS 15.0 (SPSS, Chicago, IL). p< 0.05 was considered statistically signicant.
Results
The data from mRNA and miRNA microarray analysis indicated that following sciatic nerve injury, the mRNA expression levels of BDNF were dramatically up-regulated with a peak value at 7d PNI while the expression levels of miR-1 were dramatically down-regulated with a valley value at 7d PNI, both compared to that at 0h PNI (Fig.1A).
Using miRNA target prediction sowares, we found that miR-1 could target the 3-UTR of BDNF. Moreover, TargetScan and MiRanda-based analyses revealed that 3 target sites were located in 214220bp, 392398bp, and 12941300bp at 3-UTR of BDNF, respectively (Fig.1B). Sequence alignment of these 3 miR-1 binding sites suggested that they were not conserved across all species (Fig.1B). Target site 1 was conserved among boar (S. scrofa), elephant (L. Africana), chicken (G. Gallus), and lizard (L. agilis); target site 2 was conserved among boar, cat (F. Catus), chicken, frog (X. Tropicalis), and lizard; while target site 3 was conserved among elephant and cat. But all 3 binding sites were highly conserved between human (H. Sapiens) and rats (R. Norvegicus) (Fig.1B).
To determine whether BDNF was regulated by miR-1 through direct binding to its 3-UTR, the wild-type and mutant 3-UTR of BDNF, including single target site mutant (mut1, mut2, and mut3), double target site mutant (mut1&2, mut1&3, and mut2&3), and triple target site mutant (mut1&2&3) were constructed and inserted into the downstream region of the luciferase reporter gene (Fig.1C,D).miR-1 mimic and p-Luc-UTR constructs were co-transfected into HEK 293T cells to analyze the relative lucif-erase activity. The relative luciferase activity was signicantly decreased when miR-1 mimic was co-transfected with the wild-type, single target site mutant, or double target site mutants, but was not altered when miR-1 mimic was co-transfected with triple target site mutants (Fig.1E). Notably, 3 loci of BDNF, mut1, mut2, and mut3 exhibited dierent inhibiting eects. Among cells co-transfected with miR-1 mimic plus mut1, mut2, or mut3, the reduction in relative luciferase activity was the least robust in cells co-transfected with miR-1 mimic plus mut3 (p = 0.0147), while the reduction in relative luciferase activity was the most signicant in cells co-transfected with miR-1 mimic plus mut1 (p = 0.0031) (Fig.1E). Similarly, compared with cells co-transfected with miR-1 mimic plus mut1&2 (p = 0.0091), the reduction in the relative luciferase activity was less dramatic when cells
SCIENTIFIC REPORTS
3
www.nature.com/scientificreports/
Figure 1. BDNF was a direct target of miR-1. (A) mRNA and miRNA microarray analyses showed that the expression levels of BDNF and miR-1 in the crushed sciatic nerve were changed at 0, 1, 4, 7, and 14d post nerve injury (PNI). (B) Sketch of the predicted target sites (214220bp, 392398bp, and 12941300bp) of miR-1 at the 3-UTR of BDNF, and sequence alignment of the putative miR-1 binding sites across species. (C) Sketch of the construction of wild-type and mutant p-Luc-UTR vectors. (D) Sketch of the construction of wild-type, single mutant (mut1, mut2, and mut3), double mutant (mut1&2, mut1&3, mut2&3), and triple mutant (mut1&2&3) BDNF. (E) The relative luciferase activity was analyzed aer the p-Luc-UTR vectors including 3-UTR of wild-type and mutant BDNF were co-transfected into HEK 293T cells with miR-1 mimic (miR-1) or mimic control (miR Con). Renilla luciferase vector was used as an internal control. **p<0.01, *p<0.05.
were co-transfected with miR-mimic plus mut2&3 or mut1&3 (p=0.0452, and p=0.0209, respectively) (Fig.1E). Taken together, these observations suggested that miR-1 targeted BDNF through its direct binding to the 3-UTR of BDNF. All 3 target sites of BDNF were critical for the formation of miR-1-BDNF complex but with unequal signicance. Among these 3 target sites, target site 3 (12941300bp) seemed to have the greatest impact on miRNA binding.
- To identify the eect of miR-1 on the expression of BDNF, miR-1 mimic or inhibitor was transfected in
SCIENTIFIC REPORTS
4
www.nature.com/scientificreports/
Figure 2. miR-1 suppressed BDNF expression by mRNA degradation as well as translation repression.
(A) The mRNA expression of BDNF in SCs transfected with miR-1 mimic (miR-1) and miR-1 inhibitor (Anti-miR-1) was analyzed by qRT-PCR. GAPDH was used as an internal control. (B) The protein expression of BDNF in SCs transfected with miR-1 mimic and miR-1 inhibitor was analyzed by Western blot analysis. GAPDH was used as an internal control. (C) Histogram showing relative quantitative comparisons of BDNF protein expressions. (D) The relative luciferase mRNA was analyzed aer co-transfection with wild-type or mutant BDNF plus miR-1 mimic (miR-1) or mimic control (miR Con). **p<0.01, *p<0.05.
cultured SCs, respectively. qRT-PCR analysis showed that the mRNA expressions of BDNF were signicantly suppressed by over-expression of miR-1, and were signicantly enhanced by silencing of miR-1 (Fig.2A). Western blot analysis showed that the protein expressions of BDNF were also reduced by over-expression of miR-1, and increased by silencing of miR-1 (Fig.2B,C). Moreover, miR-1 over-expression-induced decrease in BDNF protein expression was greater than that in BDNF mRNA expression, suggesting that BDNF was negatively regulated by miR-1 possibly through both mRNA degradation and translation repression.
The eect of miR-1 on BDNF mRNA expression was further determined. Co-transfection of cultured SCs with miR-1 mimic plus wild-type BDNF 3-UTR-containing plasmid signicantly decreased the relative lucif-erase mRNA level, which was calculated as the ratio of luciferase rey to Renilla luciferase mRNA (Fig.2D). In contrast, the relative luciferase mRNA level in cells transfected with miR-1 mimic plus mutant BDNF triple target site (mut 1&2&3) was not signicantly changed (Fig.2D). An inter-similar reduction in the relative lucif-erase mRNA level was observed in cultured SCs co-transfected with miR-1 mimic plus mut1, mut2, or mut1&2, respectively, but no change in the relative luciferase mRNA level was found in cultured SCs co-transfected with miR-1 mimic plus mut3, mut2&3, or mut1&3 (mut3-containing BDNF 3-UTR) (Fig.2D), suggesting that miR-1 induced BDNF mRNA degradation primarily through binding to target site 3 rather than target site 1 or 2 of BDNF 3-UTR.
To verify the correlation between miR-1 and BDNF expressions, the expression proles of miR-1 and BDNF mRNA following sciatic nerve injury were investigated by qRT-PCR. The expression of miR-1 in the injured nerve was nearly unchanged at 1 d PNI and then drastically decreased at 4, 7, and 14 d PNI with a valley value at 7 d PNI, compared to that at 0h PNI (Fig.3A). On the contrary, the mRNA expression of BDNF was signicantly increased at 1, 4, 7, and 14d PNI with a peak value at 7d PNI, compared to that at 0h PNI (Fig.3B).
The protein expression prole of BDNF following sciatic nerve injury was also investigated. Results from Western blot analysis showed that protein expression of BDNF was not signicantly increased at 1 d PNI, but was extensively increased at 4d or 7d compared to that at 0h PNI, with a peak value at 7d (Fig.3C,D). Notably,
SCIENTIFIC REPORTS
5
www.nature.com/scientificreports/
Figure 3. The temporal expression prole of miR-1 following sciatic nerve crush was negatively correlated with that of BDNF. (A) The expressions of miR-1 in the crushed sciatic nerve segments were analyzed by qRTPCR. U6 was used as an internal control. (B) The mRNA expressions of BDNF in the crushed sciatic nervewere analyzed by qPCR. GAPDH was used as an internal control. (C) The protein expressions of BDNF in the crushed sciatic nerve were analyzed by Western blots. GAPDH was used as an internal control. (D) Histogram showing relative quantitative comparisons of BDNF protein expressions at dierent time points following sciatic nerve injury. **p<0.01, *p<0.05.
the protein expression prole of BDNF was not precisely parallel to its mRNA expression prole, suggesting that BDNF might probably be regulated at post-transcriptional level. The above analyses provided further evidence that that aer peripheral nerve injury, the temporal expression prole of miR-1 was roughly inversely correlated with that of BDNF. In other words, miR-1 negatively regulated BDNF in the injured peripheral nerves.
Following peripheral nerve injury, SCs synthesize BDNF and release it into the basal laminae to promote nerve regeneration. In the current study, ELISA analysis was performed to investigate the eects of miR-1 on BDNF production from SCs. Transfection of either primary SCs or RSC96 SCs with miR-1 mimic signicantly decreased the cellular secretion of BDNF compared to that with non-targeting negative control. Inversely, transfection of either primary SCs or RSC96 SCs with miR-1 inhibitor signicantly increased the cellular secretion of BDNF compared to that with non-targeting negative control (Fig.4A,B).
To further determine whether the eects of miR-1 on BDNF secretion were through targeting the 3-UTR of BDNF, miR-1 mimic and BDNF 3-UTR plasmid were co-transfected into RSC96 SCs. Transfection with miR-1 mimic alone signicantly decreased BDNF secretion, but this reducing eect of miR-1 mimic was attenuated by co-transfection with BDNF 3-UTR plasmid (Fig.4C).
Primary SCs were transfected with miR-1 mimic, miR-1 inhibitor, and non-targeting negative controls, respectively, and then subjected to cell proliferation and migration assays. EdU incorporation results showed that over-expression of miR-1 reduced the proliferation rate of SCs to less than 50% of the control value while silencing of miR-1 increased the proliferation rate of SCs to nearly 1.5 fold the control value, suggesting that miR-1 could suppress SC proliferation (Fig.5A). Transwell migration assay results showed that SCs transfected with miR-1 mimic or miR-1 inhibitor induced a signicant decrease or increase in cell migration rate compared to SCs transfected with non-targeting negative controls, respectively, suggesting that miR-1 could also suppress SC migration (Fig.5B).
To further investigate whether the eects of miR-1 on SC proliferation and migration were recapitulated through
SCIENTIFIC REPORTS
6
www.nature.com/scientificreports/
Figure 4. miR-1 depressed the secretion of BDNF. Primary SCs (A) and RSC96 SCs (B) were transfected with miR-1 mimic (miR-1), miR-1 inhibitor (Anti-miR-1), mimic control (miR Con), or inhibitor control (Anti-miR Con), respectively. The BDNF secretion from both primary SCs and RSC96 SCs transfected with miR-1 mimic was signicantly decreased, while the BDNF secretion from both primary SCs and RSC96 SCs transfectedwith miR-1 inhibitor was signicantly increased, as compared to that from both primary SCs and RSC96 SCs transfected with control. Histogram (C) showing that miR-1-induced reduction of BDNF secretion was rescued by co-transfection with miR-1 mimic plus BDNF 3-UTR plasmid. **p<0.01, *p<0.05.
Figure 5. miR-1 decreased the proliferation and migration of SCs. Primary SCs were transfected with miR-1 mimic (miR-1), miR-1 inhibitor (Anti-miR-1), mimic control (miR Con), or inhibitor control (Anti-miR Con) respectively. (A) The proliferation rate of SCs transfected with miR-1 was signicantly decreased while the proliferation rate of SCs transfected with miR-1 inhibitor was signicantly increased compared with that of control. (B) The migration rate of SCs transfected with miR-1 mimic was signicantly decreased while the migration rate of SCs transfected with miR-1 inhibitor was signicantly increased compared with that of control. **p<0.01, *p<0.05.
down-regulation of BDNF, primary SCs were transfected with BDNF siRNA. The qRT-PCR and ELISA data conrmed that stable knockdown of BDNF was achieved (Fig.6A). BDNF knockdown led to a signicant reduction in cell proliferation or cell migration, which was similar to the inuence of miR-1 over-expression (Fig.6B). Aer primary SCs were co-transfected with BDNF siRNA and miR-1 inhibitor, miR-1 inhibitor-induced increase in cell proliferation and migration was signicantly abrogated by BDNF knockdown (Fig.6C,D). Collectively, all the results further demonstrated that BDNF was a functional mediator for miR-1 regulation of SC phenotype.
Peripheral nerve regeneration is a complex biological process that involves numerous dierentially expressed coding and non-coding RNAs. The regulatory role of miRNAs in peripheral nerve regulation has attracted recent research interest. Many previous studies report that phenotype modulation of SCs can be regulated by miRNAs aer peripheral nerve injury17. As is well known, SCs are the principal glial cells in the peripheral nervous system and play essential roles during peripheral nerve development and regeneration. Following nerve injury, SCs help the removal of myelin debris, and undergo dedierentiation, proliferation, and migration to form Bands of Bungner, thus guiding the directed growth of regenerating axons to the denervated targets22,23. Meanwhile, SCs synthesize and secrete neurotrophic factors, including nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5), which enhance the survival and growth of neurons24,25. These secreted
SCIENTIFIC REPORTS
7
www.nature.com/scientificreports/
Figure 6. BDNF knockdown attenuated the eect of miR-1. (A) The mRNA expression of BDNF as well as the BDNF secretion in primary SCs transfected with BDNF siRNA (si BDNF) was signicantly decreased as compared to that in SCs transfected with siRNA control (si Con). (B) Both the proliferation and the migration rate of SCs transfected with BDNF siRNA were signicantly decreased compared to those of SCs transfected with siRNA control. (C) The proliferation rate of SCs were signicantly increased by miR-1 inhibitor (Anti-miR-1), but was then rescued by co-transfection with miR-1 inhibitor plus BDNF siRNA (Anti-miR-1+si BDNF). (D) The migration rate of SCs were remarkably increased by miR-1 inhibitor, but was then rescued by co-transfection with miR-1 inhibitor plus BDNF siRNA. **p<0.01, *p<0.05.
neurotrophic factors, in turn, exert benecial actions on phenotype modulation of SCs and neurons, thus forming a positive feedback for nerve development and regeneration26,27. Since neurotrophic factors (including BDNF) can promote peripheral nerve regeneration, they are considered to hold great therapeutic potential for the treatment of peripheral nerve injury. The clinical use of exogenous BDNF, however, is limited by many difficulties, such as the delivery problem, maintenance of eective pharmacological dosages, and tumorigenic risk at high concentrations13,14,28.
In order to seek for an alternative to direct application of exogenous BDNF for peripheral nerve repair, the current study was performed to investigate the endogenous regulation of BDNF by miRNAs aer peripheral nerve injury. We identied that miR-1 mediated phenotype modulation of SCs by targeting BDNF, providing further evidence for miRNA-mediated post-transcriptional regulation of peripheral nerve regeneration.
In the current study, we performed qRT-PCR and Western blot analyses to verify the inverse association between the expressions of miR-1 and BDNF. Then, we demonstrated that miR-1 inhibited both the mRNA and
SCIENTIFIC REPORTS
8
www.nature.com/scientificreports/
the protein levels of BDNF by directly targeting the 3-UTR of BDNF, and showed that miR-1 also reduced the abundance of endogenous BDNF synthesized by SCs.
Target prediction algorithm as well as dual-luciferase reporter assay suggested that BDNF was a binding target of miR-1 and there were 3 binding sites of miR-1 at BDNF 3-UTR. Although all 3 target sites were involved in miR-1 binding, target site 3 might be the most eective among all sites. As a rule, miRNAs negatively regulate the expression of their target genes by promoting mRNA degradation and/or inhibiting protein translational29,30. In
the current study, we determined the relative luciferase mRNA level (as the ratio of Firey to Renilla luciferase). This level was reduced when cultured SCs were co-transfected with miR-1 plus BDNF 3-UTR containing no mutant target site 3 (including wild-type, mut1, mut2, and mut1&2), but this level was not signicantly changed when cultured SCs were co-transfected with miR-1 plus BDNF 3-UTR containing mutant target site 3 (mut3, mut2&3, and mut1&3). It was supposed that target site 3 at BDNF 3-UTR primarily aected mRNA degradation whereas target sites 1 and 2 aected protein translation.
To determine the biological role of miR-1 in phenotype modulation of SCs, cultured SCs were transfected with miR-1 mimic and with miR-1 inhibitor respectively. We found that over-expression and silencing of miR-1 caused suppressing and promoting eects on SC proliferation and migration respectively. Moreover, cultured SCs were transfected with miR-1 inhibitor in the presence or absence of BDNF siRNA. We noted that BDNF knockdown signicantly attenuated miR-1 inhibitor-induced changes in SC proliferation and migration, suggesting that BNDF was a functional mediator of miR-1 in regulating SC phenotype.
Our previous study has reported that aer sciatic nerve injury, the dierentially expressed let-7 miRNAs regulate SC phenotype by directly targeting NGF and aect sciatic nerve regeneration20. In the current study, we showed that another neurotrophic factor, BDNF, could also be regulated endogenously by a miRNA molecule. These ndings open up a bright prospect for developing a novel therapeutic strategy that bypasses the limitations of direct administration of exogenous neurotrophic factors and promotes peripheral nerve regeneration through miRNAs targeting the expression of endogenous neurotrophic factors.
In summary, we identied that miR-1 was down-regulated at 4, 7, and 14 d following sciatic nerve injury, reaching a valley value at 7d. The reduced expression of miR-1 increased the expression and secretion of BDNF, and promoted SC proliferation and migration. The data contribute to better understanding of biological processes during peripheral nerve regeneration, and provide new approach to peripheral nerve repair.
References
1. Noble, J., Munro, C. A., Prasad, V. S. & Midha, R. Analysis of upper and lower extremity peripheral nerve injuries in a population of patients with multiple injuries. J. Trauma 45, 116122 (1998).
2. Yegiyants, S., Dayicioglu, D., Kardashian, G. & Panthaki, Z. J., Traumatic peripheral nerve injury: a wartime review. J. Craniofac. Surg. 21, 9981001 (2010).
3. Battiston, B., Papalia, I., Tos, P. & Geuna, S. Chapter 1: Peripheral nerve repair and regeneration research: a historical note. Int. Rev. Neurobiol. 87, 17 (2009).
4. Gu, X. Progress and perspectives of neural tissue engineering. Front Med 9, 401411 (2015).5. Gu, X., Ding, F. & Williams, D. F. Neural tissue engineering options for peripheral nerve regeneration. Biomaterials 35, 61436156 (2014).
6. Boyd, J. G. & Gordon, T. Neurotrophic factors and their receptors in axonal regeneration and functional recovery aer peripheral nerve injury. Mol. Neurobiol. 27, 277324 (2003).
7. Braun, S., Croizat, B., Lagrange, M. C., Warter, J. M. & Poindron, P. Neurotrophins increase motoneurons ability to innervate skeletal muscle bers in rat spinal cord-human muscle cocultures. J. Neurol. Sci. 136, 1723 (1996).
8. Henderson, C. E. et al. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature 363, 266270 (1993).
9. Lykissas, M. G., Batistatou, A. K., Charalabopoulos, K. A. & Beris, A. E. The role of neurotrophins in axonal growth, guidance, and regeneration. Curr Neurovasc Res 4, 143151 (2007).
10. English, A. W., Liu, K., Nicolini, J. M., Mulligan, A. M. & Ye, K. Small-molecule trkB agonists promote axon regeneration in cut peripheral nerves. Proc. Natl. Acad. Sci. USA 110, 1621716222 (2013).
11. Wilhelm, J. C. et al. Cooperative roles of BDNF expression in neurons and Schwann cells are modulated by exercise to facilitate nerve regeneration. J. Neurosci. 32, 50025009 (2012).
12. Zhang, J. Y., Luo, X. G., Xian, C. J., Liu, Z. H. & Zhou, X. F. Endogenous BDNF is required for myelination and regeneration of injured sciatic nerve in rodents. Eur. J. Neurosci. 12, 41714180 (2000).
13. Lu, B., Nagappan, G., Guan, X., Nathan, P. J. & Wren, P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 14, 401416 (2013).
14. Nagahara, A. H. & Tuszynski, M. H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10, 209219 (2011).
15. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215233 (2009).16. Liu, B., Li, J. & Cairns, M. J. Identifying miRNAs, targets and functions. Brief Bioinform 15, 119 (2014).17. Yu, B., Zhou, S., Yi, S. & Gu, X. The regulatory roles of non-coding RNAs in nerve injury and regeneration. Prog. Neurobiol. 134, 122139 (2015).
18. Li, S. et al. Dierential gene expression proling and biological process analysis in proximal nerve segments aer sciatic nerve transection. PLoS ONE 8, e57000 (2013).
19. Yu, B. et al. miR-221 and miR-222 promote Schwann cell proliferation and migration by targeting LASS2 aer sciatic nerve injury. J. Cell Sci. 125, 26752683 (2012).20. Li, S. et al. Let-7 microRNAs regenerate peripheral nerve regeneration by targeting nerve growth factor. Mol Ther 23, 423433 (2015).
21. Yu, B. et al. miR-182 inhibits Schwann cell proliferation and migration by targeting FGF9 and NTM, respectively at an early stage following sciatic nerve injury. Nucleic Acids Res 40, 1035610365 (2012).
22. Namgung, U. The role of Schwann cell-axon interaction in peripheral nerve regeneration. Cells Tissues Organs 200, 612 (2014).23. Stoll, G., Griffin, J. W., Li, C. Y. & Trapp, B. D. Wallerian degeneration in the peripheral nervous system: participation of both Schwann cells and macrophages in myelin degradation. J. Neurocytol. 18, 671683 (1989).
24. Frostick, S. P., Yin, Q. & Kemp, G. J. Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery 18,
397405 (1998).
SCIENTIFIC REPORTS
9
www.nature.com/scientificreports/
25. Gu, X., Ding, F., Yang, Y. & Liu, J. Construction of tissue engineered nerve grafts and their application in peripheral nerve regeneration. Prog. Neurobiol. 93, 204230 (2011).
26. Chan, J. R. et al. NGF controls axonal receptivity to myelination by Schwann cells or oligodendrocytes. Neuron 43, 183191 (2004).27. Terenghi, G. Peripheral nerve regeneration and neurotrophic factors. J. Anat. 194 (Pt 1), 114 (1999).28. Gordon, T. The role of neurotrophic factors in nerve regeneration. Neurosurg Focus 26, E3 (2009).29. Ambros, V. The functions of animal microRNAs. Nature 431, 350355 (2004).30. Jinek, M. & Doudna, J. A. A three-dimensional view of the molecular machinery of RNA interference. Nature 457, 405412 (2009).
This work was supported by National Key Basic Research Program of China (2014CB542202 and 2012AA020502); National Natural Science Foundation of China (81130080, 31300879, 81471259), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).
S.L. and X.G. designed the research; S.Y., Y.Y., Q.C., X.W. and L.G. performed the experiments; S.L., Y.Y. and X.G. analyzed data; S.L., S.Y. and J.L. wrote the paper.
Competing nancial interests: The authors declare no competing nancial interests.
How to cite this article: Yi, S. et al. Regulation of Schwann cell proliferation and migration by miR-1 targeting brain-derived neurotrophic factor aer peripheral nerve injury. Sci. Rep. 6, 29121; doi: 10.1038/srep29121 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the articles Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
SCIENTIFIC REPORTS
10
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright Nature Publishing Group Jul 2016
Abstract
Peripheral nerve injury is a global problem that causes disability and severe socioeconomic burden. Brain-derived neurotrophic factor (BDNF) benefits peripheral nerve regeneration and becomes a promising therapeutic molecule. In the current study, we found that microRNA-1 (miR-1) directly targeted BDNF by binding to its 3'-UTR and caused both mRNA degradation and translation suppression of BDNF. Moreover, miR-1 induced BDNF mRNA degradation primarily through binding to target site 3 rather than target site 1 or 2 of BDNF 3'-UTR. Following rat sciatic nerve injury, a rough inverse correlation was observed between temporal expression profiles of miR-1 and BDNF in the injured nerve. The overexpression or silencing of miR-1 in cultured Schwann cells (SCs) inhibited or enhanced BDNF secretion from the cells, respectively, and also suppressed or promoted SC proliferation and migration, respectively. Interestingly, BDNF knockdown could attenuate the enhancing effect of miR-1 inhibitor on SC proliferation and migration. These findings will contribute to the development of a novel therapeutic strategy for peripheral nerve injury, which overcomes the limitations of direct administration of exogenous BDNF by using miR-1 to regulate endogenous BDNF expression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer




